Skip to main content
OpenTrials
Completed

NCT Number: NCT01153984

A Study to Assess Biomarkers Impact on Participants Response to Erlotinib Treatment for First-line Non-Small Cell Lung Cancer With Endothelial Growth Factor Receptor (EGFR) Activating Mutations

This open-label, single-arm, multi-center study will evaluate the progression-free survival in participants with histologically documented, advanced and/or metastatic chemotherapy naive, non-small cell lung cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) positive mutations and receiving erlotinib treatment. The anticipated time on study treatment is until disease progression, unacceptable toxicity, withdrawal due to any reason or death.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Carcinoma，Non-Small-Cell Lung Bronchial Neoplasms Carcinoma, Bronchogenic Carcinoma, Non-Small-Cell Lung Lung Diseases Lung Neoplasms Neoplasms Neoplasms by Site Respiratory Tract Diseases Respiratory Tract Neoplasms Thoracic Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

County Hospital Alba; Oncology, Alba Iulia, Romania

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Histological documented adenocarcinoma, locally advanced - Stage IIIB, metastatic - Stage IV or recurrent non-squamous NSCLC
  • Activated EGFR mutation positive status (Exons 19 and 21) for treatment phase
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1
  • Life expectancy greater than or equal to (≥) 12 weeks
  • Evidence of disease with at least one measurable disease evaluation on Response Evaluation Criteria in Solid Tumors (RECIST)
  • Adequate hematological , liver and renal function

Exclusion criteria

  • Known hypersensitivity to erlotinib or any of its excipients
  • Squamous non-small cell or small cell tumors or absence of histological report
  • Neoadjuvant/adjuvant chemotherapy within 6 months prior to enrollment
  • Prior exposure to inhibitors of EGFR
  • Prior chemotherapy or treatment with another systemic anti-cancer agent for the treatment of the participant's current stage of disease
  • Any significant ophthalmologic abnormality, especially severe dry eye syndrome, keratoconjunctivitis sicca, Sjögren syndrome, severe exposure keratitis or any other disorder likely to increase the risk of corneal epithelial lesions
  • Radical radiotherapy with curative intent within 28 days prior to enrollment
  • Any active non-controlled systemic disease

Treatment and study plan

Erlotinib

Drug

Erlotinib 150 mg oral doses will be administered daily.

Other names: Tarceva

Primary outcomes

  1. Progression-Free Survival (PFS), as Assessed by Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)

    Time frame: Baseline up to approximately 4 years

    PFS was the time from inclusion in the study to the date of first documented PD or death from any cause, whichever occurred first. Participants without event were censored at the date of the last tumor assessment where non-progression was documented. If a participant received a second anti-cancer therapy without prior documentation of disease progression, the participant was censored at the date of last tumor assessment before starting new chemotherapy. Analysis was performed using Kaplan-Meier method. PD was defined as at least a 20% increase in the sum of LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of 1 or more new lesions.

Secondary outcomes

  1. Time to Disease Progression, as Assessed by Investigator Using RECIST v1.1

    Time frame: Baseline up to approximately 4 years

    Time to disease progression was defined as the time from baseline evaluation to the first date PD was recorded. Participants without progression were censored at the date of last tumor assessment where non-progression was documented. PD was defined as at least a 20% increase in the sum of LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of 1 or more new lesions.

  2. Percentage of Participants With Complete Response (CR) And Partial Response (PR) as Assessed by the Investigator Using RECIST v1.1

    Time frame: Baseline up to approximately 4 years

    CR was defined as the disappearance of all target lesions, and PR was defined as at least a 30% decrease in the sum of the longest diameter compared to baseline.

  3. Percentage of Participants Who Were Alive One Year After Study Treatment Initiation

    Time frame: Year 1

  4. Percentage of Participants by Localization of PD, as Assessed by Investigator Using RECIST v1.1

    Time frame: Baseline up to approximately 4 years

    PD was assessed using RECIST v1.1. PD was defined as at least a 20% increase in the sum of LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of 1 or more new lesions. Percentage of participants by localization of PD were reported. Localization included: Left lung inferior lobe; Para-aortic; Left lung upper lobe; Right lung inferior lobe; and Infracranial.

  5. Number of EGFR Positive Participants Classified Based on Smoking Status

    Time frame: Day 1

    Participants were asked: "Have you smoked at least 100 cigarettes in your entire life?" and "Do you now smoke cigarettes every day, some days, or not at all?" Responses were grouped into three categories: Current Smoker, Former Smoker, and Non-Smoker. Participants who reported smoking at least 100 cigarettes in their lifetime and who, at the time of survey, smoked either every day or some days were defined as 'Current smoker'. Participants who reported smoking at least 100 cigarettes in their lifetime and who, at the time of the survey, did not smoke at all were defined as 'Former smoker'. Participants who reported never having smoked 100 cigarettes were defined as 'Non-smoker'.

  6. Number of EGFR Positive Participants Classified Based on Type of EGFR Mutations

    Time frame: Day 1

    Participants with NSCLC have tumor associated with EGFR mutations. These mutations occur within EGFR Exons 18-21, which encodes a portion of the EGFR kinase domain.

  7. Percentage of Similar EGFR Mutations Between Matched Plasma and Tumor Tissue Samples

    Time frame: Baseline up to approximately 4 years

Sponsors and collaborators

Lead sponsor

Hoffmann-La Roche

Industry

Registry information

Official study title

Biomarkers Impact on the Response to Treatment With Erlotinib in First Line Non-small Cell Lung Cancer With EGFR Activating Mutations - BIOTEC

Acronym: BIOTEC

Important dates

Study start
2011
Primary completion
2015
Study completion
2015
First posted
Jun 30, 2010
Registry last updated
Apr 13, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.